Plain-English translation of NCT05552222 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Myeloma research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing whether two newer medications called and , when combined with existing myeloma treatments, can help people with newly diagnosed multiple myeloma live longer and healthier lives. You would be randomly assigned to receive one of three treatment combinations: the new medication combined with two existing drugs, or the current standard three-drug combination. The goal is to find out which approach works best.
Multiple myeloma is a serious blood cancer, and while current treatments help many patients, researchers want to see if adding these newer medications can improve outcomes even further. This medication represents a new type of approach to fighting myeloma, so this study will help doctors understand whether it should become part of standard care.
You likely qualify if…
You likely don't qualify if…
You will visit a hospital or clinic regularly to receive your assigned treatment combination, which includes injections under the skin and oral medications taken at home. The exact schedule depends on which treatment group you are randomly assigned to, but typically involves regular appointments over several months for monitoring, blood tests, and receiving your medication. You will be followed closely by your care team to watch for side effects and see how well the treatment is working.
AI-generated summary from trial data · Jul 12, 2026 · Not medical advice
United States